Last reviewed: June 9, 2026
Last updated: June 9, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
GLP-1 medications have transformed weight management for over 15 million Americans, yet not everyone qualifies immediately. Understanding the criteria helps you determine whether semaglutide injection, oral semaglutide, or other GLP-1 therapies align with your health needs and medical history.
Body Mass Index and Weight-Related Health Criteria
Body mass index (BMI) remains a primary screening tool for GLP-1 eligibility. Adults with a BMI of 30 or higher generally qualify, while individuals with a BMI between 27 and 29.9 may qualify if they have weight-related conditions like type 2 diabetes, hypertension, or sleep apnea. PlexusDx evaluates your complete metabolic profile rather than BMI alone, recognizing that health extends beyond a single number.
Weight-related complications matter significantly in eligibility decisions. If you carry excess weight that impacts joint health, cardiovascular function, or metabolic markers, you become a stronger candidate for GLP-1 therapy. PlexusDx reviews blood pressure, cholesterol levels, and glucose metabolism to paint a full picture of your metabolic health.
Metabolic and Blood Sugar Control Considerations
Type 2 diabetes diagnosis or prediabetes significantly influences GLP-1 eligibility, since these medications were originally developed to improve glucose control. Fasting blood sugar above 100 mg/dL or hemoglobin A1C above 5.7% suggests metabolic dysfunction that GLP-1 therapy addresses effectively. PlexusDx reviews your glucose patterns and insulin resistance markers to assess whether semaglutide injection or tirzepatide matches your metabolic needs.
Cardiovascular risk factors strengthen the case for GLP-1 treatment. Individuals with elevated triglycerides, low HDL cholesterol, or a history of heart disease often qualify because GLP-1 medications improve multiple cardiovascular markers. Recent research shows these compounds reduce heart attack and stroke risk by 20-25% in high-risk populations, expanding eligibility beyond weight loss alone.
Medical History and Medication Interactions
Your medication history influences GLP-1 eligibility decisions. Certain diabetes drugs work synergistically with semaglutide or tirzepatide, while others may create redundancy. PlexusDx reviews your complete medication list to ensure GLP-1 therapy complements rather than conflicts with existing treatments, protecting both safety and efficacy.
Gastrointestinal surgery history, thyroid cancer risk, or pancreatitis history may affect eligibility or require closer monitoring. PlexusDx screens for personal or family history of medullary thyroid carcinoma because GLP-1 medications carry a theoretical risk in susceptible individuals. Honest disclosure of your complete medical background ensures you receive appropriate therapy that prioritizes your safety.
Age, Pregnancy, and Special Population Considerations
Age influences GLP-1 eligibility, with most medications approved for adults 18 and older. Elderly patients may qualify but often receive lower starting doses to minimize gastrointestinal side effects common in older populations. PlexusDx screens for age-related kidney function because GLP-1 medications require adequate renal clearance to prevent medication buildup.
Pregnancy and breastfeeding eliminate GLP-1 eligibility temporarily, since safety data in pregnant women remains limited. Women of childbearing age who take semaglutide injection or other GLP-1 compounds should use effective contraception. PlexusDx confirms reproductive plans before initiating therapy, ensuring your treatment aligns with your family-building timeline.
Genetic Predisposition and Personalized Eligibility
Beyond standard medical criteria, genetic variations influence how your body responds to GLP-1 therapy. The PlexusDx Precision Peptide Genetic Test analyzes key variants including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 to predict your individual response potential. Some genetic profiles indicate higher efficacy with semaglutide, while others suggest tirzepatide or dual-compound therapy may work better.
Mapping 14 metabolic pathways and 150+ genetic insights helps PlexusDx match you with the ideal GLP-1 medication from day one. This precision approach means you're not guessing which compound will work—your genetics inform the clinical decision. The $99 Precision Peptide Genetic Test (available after your first month) transforms standard eligibility into truly personalized therapy that maximizes your results.
How PlexusDx Evaluates Your Individual Eligibility
PlexusDx uses a comprehensive evaluation process combining standard medical criteria with advanced metabolic assessment. Your initial consultation reviews weight history, metabolic markers, medication list, and family health patterns to establish baseline eligibility. PlexusDx serves all 50 states without requiring insurance, making assessment accessible regardless of coverage gaps.
If you qualify, PlexusDx begins with compounded semaglutide injection at $149 per month—the same flat price whether your dose eventually increases to address your individual needs. Your dose may need to go up. Your price won't. This transparent pricing structure eliminates hidden costs and dose-based surcharges, allowing you to focus on results rather than financial surprises.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Do I need a BMI of 30 or higher to qualify for GLP-1 medications?
Not necessarily. While BMI 30+ is common, individuals with BMI 27-29.9 qualify if they have weight-related conditions like type 2 diabetes, hypertension, or obstructive sleep apnea. PlexusDx evaluates your complete metabolic and health profile rather than BMI alone, ensuring eligibility decisions reflect your real health risks.
Can I take GLP-1 therapy if I don't have diabetes?
Yes. GLP-1 medications like semaglutide help with weight loss and metabolic health even without diabetes diagnosis. If you have prediabetes, cardiovascular risk factors, or excess weight affecting your health, you likely qualify. PlexusDx reviews your specific health markers to determine eligibility beyond diabetes status alone.
What medications conflict with semaglutide or tirzepatide?
Certain diabetes drugs and weight loss medications may create redundancy or safety concerns when combined with GLP-1 therapy. PlexusDx reviews your complete medication list during your initial evaluation to identify conflicts and adjust your treatment plan accordingly, ensuring safe and effective therapy.
Does PlexusDx require insurance approval or medical records from my doctor?
No. PlexusDx serves all 50 states with no insurance requirement and no membership fees. You can start with an initial consultation, and PlexusDx may request recent labs or records to verify eligibility. HSA and FSA plans are accepted, making compounded semaglutide injection starting at $149/month even more affordable.
How does the Precision Peptide Genetic Test change my eligibility or treatment?
The $99 test (available after your first month) analyzes key variants affecting GLP-1 response pathways, helping PlexusDx predict whether semaglutide, tirzepatide, or dual compounds work best for your genetics. This doesn't change eligibility but optimizes which medication matches your biology, improving outcomes before you commit to a specific therapy.
Are there health conditions that make me ineligible for GLP-1 therapy?
Personal or family history of medullary thyroid carcinoma, severe kidney disease, or certain gastrointestinal conditions may affect eligibility. Recent pancreatitis also requires careful assessment. PlexusDx screens for these contraindications during your consultation, ensuring any therapy recommended prioritizes your safety and aligns with your medical history.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Does Taking Ozempic Cause Constipation? Tips for Relief
How Many Months to Lose Weight on Ozempic? A Comprehensive Guide to Your Weight Loss Journey